Hanmi Pharm launches Korea’s first modified drug for influenza, ‘Hanmi Flu’
Hanmi Pharm(CEO Kwan-soon Lee, www.hanmi.co.kr) announced to launch Hanmi Flu, the Korea’s first incrementally modified drug for influenza on the 16th.
The company stated Hanmi Flu(generic name: oseltamivir), a treatment having effects for influenza A & B, which acquired approval as an increment...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
